Technical Use of Angiotensin I/II (1-5) in RAS Research

What This Product Solves

Angiotensin I/II (1-5) is a defined Asp-Arg-Val-Tyr-Ile peptide fragment derived from the enzymatic cleavage of angiotensin I and II. It serves as a standardized tool for researchers investigating the renin-angiotensin system (RAS), specifically in the context of blood pressure regulation and aldosterone release stimulation. By providing a reproducible substrate for RAS pathway modeling, Angiotensin I/II (1-5) facilitates controlled studies of vasoconstrictor peptide fragment activity, supporting experiments in hypertension and renal function research where precise control of peptide identity and concentration is essential (internal guide). This product is optimized for workflows requiring high-purity, sequence-defined peptide input, reducing variability in assays dependent on the Asp-Arg-Val-Tyr-Ile motif.

Protocol Parameters

• assay: Stock solution preparation | value_with_unit: ≥66.5 mg/mL in DMSO; ≥69.5 mg/mL in ethanol | applicability: Solubilization prior to RAS pathway assays | rationale: Angiotensin I/II (1-5) is insoluble in water but readily dissolves at high concentrations in DMSO or ethanol, enabling accurate dosing in cell or tissue-based experiments | source_type: product_spec
• assay: Storage conditions | value_with_unit: -20°C (solid form) | applicability: Long-term preservation of peptide integrity | rationale: Freezing at -20°C minimizes hydrolysis and degradation, ensuring batch-to-batch consistency for experimental workflows | source_type: product_spec
• assay: Working concentration (in vitro RAS modeling) | value_with_unit: 1–10 μM (workflow recommendation) | applicability: Typical in vitro exposure range for modeling vasoconstrictor and aldosterone signaling pathways | rationale: This concentration range aligns with established practice in peptide hormone vasoconstriction studies, allowing for clear signal detection without excessive substrate consumption | source_type: workflow_recommendation

Workflow Setup and QC Checklist

• Verify peptide identity and integrity upon receipt using mass spectrometry or HPLC, as the molecular weight is 664.75 Da and the formula is C30H48N8O9 (product_spec).
• Prepare stock solutions in DMSO or ethanol only; avoid water to prevent precipitation or incomplete solubilization.
• Aliquot stocks into single-use volumes to minimize freeze-thaw cycles and maintain sample stability at -20°C.
• Prior to assay setup, dilute stocks into physiological buffers immediately before use to avoid peptide degradation.
• Include vehicle controls (DMSO or ethanol) in experimental design to distinguish peptide-specific effects from solvent artifacts.
• Reference the Technical Guide for Angiotensin I/II (1-5) in RAS Research for tips on integrating this peptide into hypertension and renal workflows.

Common Failure Modes and Fixes

• Incomplete dissolution in aqueous media: Angiotensin I/II (1-5) is insoluble in water; dissolve first in DMSO or ethanol, then dilute into buffer while vortexing to avoid precipitation.
• Peptide degradation on repeated freeze-thaw: Aliquot stocks and avoid repeated thawing; always store at -20°C in tightly sealed vials.
• Unexplained variability in assay results: Confirm peptide lot integrity by analytical QC and standardize solvent content across all test and control groups.
• Off-target effects due to extraneous application: Restrict use to RAS-focused blood pressure regulation and aldosterone signaling studies, as highlighted in the Technical Use of Angiotensin I/II (1-5) in RAS Research article.

Scope and Limitations

Angiotensin I/II (1-5) is specifically tailored for controlled modeling of the renin-angiotensin system, including hypertension research, aldosterone release stimulation, and renal physiology. Its use is not appropriate for workflows outside these domains, such as unrelated peptide hormone signaling or cross-system studies, due to its unique solubility and mechanistic properties (internal article). The peptide should not be used in water-based stock preparations, nor should it be assumed to model other angiotensin fragments beyond the Asp-Arg-Val-Tyr-Ile sequence. Correct workflow integration and adherence to recommended storage and handling protocols are essential for reproducibility.

Conclusion

For researchers modeling the renin-angiotensin system, Angiotensin I/II (1-5) offers a high-purity, sequence-defined tool that supports reproducible experiments in blood pressure regulation and aldosterone signaling. By following best practices for solubilization, storage, and experimental design, users can minimize sources of error and ensure the reliability of their cardiovascular and renal research data. For further guidance, consult available technical guides and restrict use to validated RAS-focused workflows.